Diabetes / Metabolic
Diabetes and metabolic medicine updates, trial evidence, drug mechanisms and CPD resources across glucose lowering, weight management and cardiometabolic risk.
Latest Guidelines
Insulin efsitora alfa for treating type 2 diabetes
Insulin efsitora alfa is recommended as a treatment option for type 2 diabetes and should be considered within NICE guidance criteria—confirm patient eligibility and glycaemic control…
Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes
Teplizumab is recommended for people aged 8 years and over with stage 2 type 1 diabetes to delay progression to stage 3; discuss with patients/families the…
2022 EASD/ESC Guidelines on Diabetes and Cardiovascular Disease
This EASD guideline addresses 2022 EASD/ESC Guidelines on Diabetes and Cardiovascular Disease in Diabetes / Metabolic. Use it to review current recommendation wording, eligibility criteria, and…
2023 ADA/EASD Consensus Report: Management of Hyperglycaemia in Type 2 Diabetes
Joint consensus update prioritising SGLT2 inhibitors and GLP-1 receptor agonists based on cardiovascular and renal comorbidities. Introduces individualised glucose targets and deprescribing guidance.
Tirzepatide for Managing Overweight and Obesity (NICE TA1026)
Prescribe tirzepatide to adults with BMI ≥35 kg/m² or BMI 30–34.9 kg/m² with weight-related comorbidities, initiating treatment in specialist weight management services or trained general practice…
Semaglutide for Managing Overweight and Obesity (NICE TA875)
Initiate semaglutide only in specialist obesity services or via shared care with clear primary-secondary care protocols for adults with BMI ≥30 kg/m² or BMI ≥27 kg/m²…
Trial Radar
Nutritional Supplementation on Physiological and Metabolic Markers in Females
Trial testing whether a 12-week supplement containing myo-inositol, berberine, cinnamon, and chromium improves body composition in women aged…
NAA Study on Ubiquinol on Fatigue and Muscle Strength in Healthy Adults Taking GLP-1 Agonists
Ubiquinol supplement versus placebo to reduce fatigue and preserve muscle strength in adults taking GLP-1 weight loss medications.
PHASE3A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
This study looks at how well a medicine called orforglipron works compared to another medicine called dulaglutide in…
NAA Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing Haemodialysis
Diabetes is the leading cause of kidney failure in the UK. Many people with diabetes and advanced kidney…
Clinical News
Weekly type 2 diabetes jab could replace daily injections
Weekly insulin injections (icodec) offer potential to improve adherence by reducing dosing frequency from daily to once-weekly for…
07 Aug 2026Obesity rates have doubled in England since 1993 – what’s going on?
Obesity prevalence in England has doubled since 1993, representing an additional 7 million adults—a substantial public health burden…
22 Jul 2026Rise in women in their 20s developing Type 2 diabetes
Young women in their 20s in England are developing type 2 diabetes at increasing rates, representing a shift…
22 Jul 2026More young women in their 20s are getting type 2 diabetes
Type 2 diabetes incidence is rising significantly in women aged in their 20s in England, requiring heightened clinical…
Relevant Mechanisms
GLP-1 Receptor Agonism
GLP-1 Receptor Agonism is a clinically relevant Drug Science explainer. Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted from intestinal…
MechanismHMG-CoA Reductase — Statins
HMG-CoA Reductase — Statins is a clinically relevant Drug Science explainer. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase catalyses the rate-limiting step…
MechanismPCSK9 Inhibition
PCSK9 Inhibition is a clinically relevant Drug Science explainer. PCSK9 (proprotein convertase subtilisin/kexin type 9) is a serine protease secreted…
MechanismSGLT-2 Inhibition
SGLT-2 Inhibition is a clinically relevant Drug Science explainer. Sodium-glucose cotransporter-2 (SGLT-2) is a high-capacity, low-affinity transporter expressed almost exclusively…
CPD, Podcasts & Webinars
SGLT2 Inhibitors: From Glycaemia to Heart Failure and Chronic Kidney Disease
recorded webinar focused on SGLT2 Inhibitors in diabetes and metabolic medicine. Use the recording with the slide outline…
webinarGLP-1 Agonists: Semaglutide, Tirzepatide and the Cardiovascular Revolution
recorded webinar focused on GLP-1 Agonists in diabetes and metabolic medicine. Use the recording with the slide outline…
podcastGLP-1 Agonists: Semaglutide, Tirzepatide and the Cardiovascular Revolution
GLP-1 receptor agonists mimic gut-derived GLP-1: they increase glucose-dependent insulin release, suppress glucagon and slow gastric emptying. Semaglutide…
podcastSGLT2 Inhibitors: From Glycaemia to Heart Failure and Chronic Kidney Disease
SGLT2 inhibitors block glucose reabsorption in the proximal renal tubule, causing glycosuria with effects that extend beyond HbA1c…
cpd moduleNICE NG28: Type 2 Diabetes in Adults — 2024 Update
Apply NICE NG28 updates to type 2 diabetes treatment sequencing, including when SGLT2 inhibitors or GLP-1 receptor agonists…
cpd moduleCardiovascular Risk Reduction — Latest Evidence 2024
Use QRISK3 and clinical risk factors to identify patients who need lipid-lowering intensification. Apply statin, ezetimibe, PCSK9 inhibitor…
Follow Diabetes / Metabolic safety updates
Get MHRA safety alerts and clinically relevant updates for this specialty in your ClinicaliQ digest.
Follow Diabetes / Metabolic
Choose guideline, trial, Drug Science and education updates for this specialty.